128O - Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with untreated EGFRm advanced NSCLC: FLAURA post-progression...

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session ESMO-IASLC Best Abstracts
Topics Non-Small-Cell Lung Cancer, Metastatic
Cancer Immunology and Immunotherapy
Lung and other Thoracic Tumours
Presenter David Planchard
Citation Journal of Thoracic Oncology (2018) 13 (supp_4): S1-S139.
Authors D. Planchard1, M. Boyer2, J. Lee3, A. Dechaphunkul4, P. Cheema5, T. Takahashi6, A. Todd7, A. McKeown7, Y. Rukazenkov7, Y. Ohe8
  • 1Department Of Medical Oncology, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 2Department Of Medical Oncology, Chris O'Brien Lifehouse, 2050 - Camperdown/AU
  • 3National University Bundang Hospital, 463-707 - Seongnam/KR
  • 4Division Of Medical Oncology, Department Of Internal Medicine, Prince of Songkla University Faculty of Medicine, 90110 - Songkla/TH
  • 5Faculty Of Medicine And Medical Oncology, William Osler Health System, University of Toronto, M4N 3M5 - Toronto/CA
  • 6Division Of Thoracic Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 7AstraZeneca, Cambridge/GB
  • 8Department Of Thoracic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP

Abstract

In the FLAURA phase 3 study, the third-generation EGFR-TKI osimertinib significantly improved progression-free survival (PFS) vs SoC EGFR-TKIs (gefitinib or erlotinib) in pts with previously untreated Ex19del/L858R (EGFRm) advanced NSCLC (hazard ratio [HR] 0.46 [95% CI 0.37, 0.57]; p < 0.001). Interim overall survival (OS) data was encouraging but not formally statistically significant (HR 0.63 [95% CI 0.45, 0.88]; p = 0.007). Here we report exploratory post-progression outcomes.